Oregon Public Employees Retirement Fund Trims Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Oregon Public Employees Retirement Fund lowered its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 2.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,350 shares of the specialty pharmaceutical company’s stock after selling 272 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Jazz Pharmaceuticals were worth $1,521,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CWA Asset Management Group LLC acquired a new stake in Jazz Pharmaceuticals during the third quarter valued at approximately $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Jazz Pharmaceuticals by 135.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after buying an additional 100,112 shares in the last quarter. Centre Asset Management LLC acquired a new stake in Jazz Pharmaceuticals during the fourth quarter valued at approximately $9,335,000. Moloney Securities Asset Management LLC acquired a new stake in Jazz Pharmaceuticals during the fourth quarter valued at approximately $464,000. Finally, Pacer Advisors Inc. raised its stake in Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after buying an additional 278,465 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Up 0.2 %

JAZZ opened at $143.53 on Friday. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $148.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market cap of $8.68 billion, a P/E ratio of 20.22, a P/E/G ratio of 1.04 and a beta of 0.56. The stock’s 50 day moving average price is $126.28 and its 200 day moving average price is $118.79.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of several research reports. Piper Sandler restated an “overweight” rating and set a $176.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday. Robert W. Baird increased their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. TD Cowen dropped their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. Finally, Cantor Fitzgerald cut Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and increased their price target for the stock from $140.00 to $150.00 in a research report on Wednesday. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $182.47.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the completion of the transaction, the chief executive officer now directly owns 439,744 shares of the company’s stock, valued at approximately $53,785,088.64. This trade represents a 0.34 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 5,053 shares of company stock worth $617,442 in the last three months. 4.20% of the stock is owned by company insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.